A detailed history of Valley Brook Capital Group, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Valley Brook Capital Group, Inc. holds 7,470 shares of BMY stock, worth $434,978. This represents 0.28% of its overall portfolio holdings.

Number of Shares
7,470
Previous 8,345 10.49%
Holding current value
$434,978
Previous $346,000 11.56%
% of portfolio
0.28%
Previous 0.27%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024

SELL
$39.66 - $51.75 $34,702 - $45,281
-875 Reduced 10.49%
7,470 $386,000
Q2 2024

Jul 26, 2024

SELL
$40.25 - $52.99 $40,250 - $52,990
-1,000 Reduced 10.7%
8,345 $346,000
Q1 2024

May 01, 2024

SELL
$47.98 - $54.4 $106,995 - $121,312
-2,230 Reduced 19.27%
9,345 $506,000
Q4 2023

Feb 06, 2024

SELL
$48.48 - $57.85 $9,696 - $11,570
-200 Reduced 1.7%
11,575 $593,000
Q2 2023

Jul 31, 2023

SELL
$63.71 - $70.74 $19,113 - $21,222
-300 Reduced 2.48%
11,775 $753,000
Q1 2023

May 04, 2023

BUY
$65.71 - $74.53 $2,956 - $3,353
45 Added 0.37%
12,075 $836,000
Q1 2022

May 02, 2022

BUY
$61.48 - $73.72 $7,131 - $8,551
116 Added 0.97%
12,030 $878,000
Q4 2021

Feb 03, 2022

SELL
$53.63 - $62.52 $5,363 - $6,252
-100 Reduced 0.83%
11,914 $742,000
Q3 2021

Oct 21, 2021

BUY
$59.17 - $69.31 $299,991 - $351,401
5,070 Added 73.01%
12,014 $710,000
Q2 2021

Jul 22, 2021

BUY
$61.91 - $67.42 $14,548 - $15,843
235 Added 3.5%
6,944 $463,000
Q1 2021

May 06, 2021

BUY
$59.34 - $66.74 $4,806 - $5,405
81 Added 1.22%
6,709 $423,000
Q4 2020

Mar 19, 2021

BUY
$57.74 - $65.43 $382,700 - $433,670
6,628 New
6,628 $411,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $124B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Valley Brook Capital Group, Inc. Portfolio

Follow Valley Brook Capital Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Valley Brook Capital Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Valley Brook Capital Group, Inc. with notifications on news.